so asserted in this 
comment that the tests conducted involved the equivalent of two 
servings of SPLENDA Granular, rather than one, and that this was not 
taken into consideration by the FDA.
    (Response) FDA agrees that a more appropriate conclusion would have 
been that the submitted evidence is insufficient to establish the 
eligibility of the sucralose-maltodextrin formulation for the claim, 
rather than concluding that the available evidence shows the use of the 
dental caries health claim i